Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-467-4577
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees49
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions
What is Allena Pharmaceuticals' stock symbol?
Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."
How were Allena Pharmaceuticals' earnings last quarter?
Allena Pharmaceuticals Inc (NASDAQ:ALNA) posted its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.01. View Allena Pharmaceuticals' Earnings History.
When is Allena Pharmaceuticals' next earnings date?
What price target have analysts set for ALNA?
5 equities research analysts have issued twelve-month price objectives for Allena Pharmaceuticals' stock. Their forecasts range from $4.00 to $31.00. On average, they expect Allena Pharmaceuticals' stock price to reach $20.60 in the next year. This suggests a possible upside of 1,013.5% from the stock's current price. View Analyst Price Targets for Allena Pharmaceuticals.
What is the consensus analysts' recommendation for Allena Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allena Pharmaceuticals.
Has Allena Pharmaceuticals been receiving favorable news coverage?
News articles about ALNA stock have trended very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Allena Pharmaceuticals earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Allena Pharmaceuticals.
Are investors shorting Allena Pharmaceuticals?
Allena Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 94,000 shares, an increase of 5.3% from the September 30th total of 89,300 shares. Based on an average trading volume of 79,100 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.8% of the company's stock are sold short. View Allena Pharmaceuticals' Current Options Chain.
Who are some of Allena Pharmaceuticals' key competitors?
Some companies that are related to Allena Pharmaceuticals include La Jolla Pharmaceutical (LJPC), X4 Pharmaceuticals (XFOR), Dyadic International (DYAI), Jounce Therapeutics (JNCE), Aptose Biosciences (APTO), Gamida Cell (GMDA), Acorda Therapeutics (ACOR), Nantkwest (NK), Novavax (NVAX), Axcella Health (AXLA), Windtree Therapeutics (WINT), Fennec Pharmaceuticals (FENC), Adaptimmune Therapeutics (ADAP), Polarityte (PTE) and Erytech Pharma (ERYP).
What other stocks do shareholders of Allena Pharmaceuticals own?
Who are Allena Pharmaceuticals' key executives?
Allena Pharmaceuticals' management team includes the folowing people:
- Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 66)
- Dr. Louis Brenner, Pres, CEO & Director (Age 49)
- Mr. Edward J. Wholihan, CFO and VP of Fin. & Admin. (Age 59)
- Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 54)
- Mr. Hugh Wight, Sr. VP of Technical Operations
When did Allena Pharmaceuticals IPO?
(ALNA) raised $80 million in an IPO on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Allena Pharmaceuticals' major shareholders?
Which major investors are buying Allena Pharmaceuticals stock?
How do I buy shares of Allena Pharmaceuticals?
Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Allena Pharmaceuticals' stock price today?
One share of ALNA stock can currently be purchased for approximately $1.85.
How big of a company is Allena Pharmaceuticals?
Allena Pharmaceuticals has a market capitalization of $43.41 million. The company earns $-35,650,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Allena Pharmaceuticals employs 49 workers across the globe.View Additional Information About Allena Pharmaceuticals.
What is Allena Pharmaceuticals' official website?
How can I contact Allena Pharmaceuticals?
Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.
MarketBeat Community Rating for Allena Pharmaceuticals (NASDAQ ALNA)
MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
